New York, NY -- (SBWIRE) -- 01/13/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: TriQuint Semiconductor (NASDAQ:TQNT), Rigel Pharmaceuticals, Inc (NASDAQ:RIGL), Gafisa SA (ADR) (NYSE:GFA), DURECT Corporation (NASDAQ:DRRX)
TriQuint Semiconductor (NASDAQ:TQNT) showed a volume of 1.16 million shares by the end of last trade whereas the average volume of the stock remained 1.70 million shares. The stock opened the session at $8.21 but then moved to $8.17. At that price, the stock showed a negative performance of -0.12%. TriQuint Semiconductor, Inc. provides a portfolio of radio frequency (RF) solutions. The Company is a supplier of both active and passive technologies. It designs, develop and manufacture these power amplifier, switch and filters modules in-house. It focuses on three end markets in the electronic communications system industry: mobile devices, networks, and defense & aerospace. It offers an array of filtering, switching and amplification products for RF, microwaves and millimeter-wave applications.
Will TQNT Get Buyers Even After The Recent Rally? Find Out Here
Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) opened the session at $3.25 and closed the session at $3.30. The stock showed a positive performance of 4.6% in previous trading session. Traded with volume of 1.16 million shares in the prior session and the average volume of the stock remained 1.17 million shares. Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. As of December 31, 2011, product development programs included fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis (RA) with its partner AstraZeneca (AZ); R343, an inhaled SYK inhibitor for asthma and R333,
For How Long RIGL will fight for Profitability? Read This Trend Analysis report
Gafisa SA (ADR) (NYSE:GFA) opened the session at $2.91 and closed the session at $2.89. Traded with volume of 1.16 million shares in the prior session and the average volume of the stock remained 1.53 million shares. The beta of the stock remained 2.56. Gafisa SA is a Brazil-based company engaged in the homebuilding and real estate operations. The Company is involved in the promotion, administration, purchase, sale and trade of real estate properties; provision of financing services to real estate customers; construction and provision of civil engineering services, and development and implementation of marketing strategies related to its own or third party real estate projects. The Company divides its business into three segments: Gafisa,
Is GFA a Solid Investment at These Levels? Read This Report For Details
DURECT Corporation (NASDAQ:DRRX) the stock decreased -2.55% and finished the session at $1.91. Traded with volume of 1.15 million shares in the prior session and the average volume of the stock remained 736,841 shares. The beta of the stock remained 1.55. Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company’s product pipeline, as of December 31, 2012, consisted of eight investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA), with one program in Phase III with an NDA in preparation, two programs in Phase II and three programs in Phase I. The Company’s products candidates include Remoxy,
Will DRRX Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)